Comparative Pharmacology
Head-to-head clinical analysis: EMBLAVEO versus HEPARIN SODIUM 10 000 UNITS IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMBLAVEO versus HEPARIN SODIUM 10 000 UNITS IN DEXTROSE 5.
EMBLAVEO vs HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EMBLAVEO is a combination of a beta-lactam antibiotic (cefepime) and a beta-lactamase inhibitor (enmetazobactam). Enmetazobactam inhibits a broad range of beta-lactamases, including ESBLs and AmpC, thereby protecting cefepime from hydrolysis and extending its spectrum of activity against beta-lactamase-producing Gram-negative bacteria.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (Xa), thereby preventing clot formation and extension.
EMBLAVEO (imipenem/cilastatin/relebactam) is administered intravenously. The recommended adult dose is 1.25 g (imipenem 500 mg, cilastatin 500 mg, relebactam 250 mg) every 6 hours infused over 30 minutes.
IV continuous infusion: initial bolus 80 units/kg, then maintenance 18 units/kg/hour; titrate to aPTT 1.5-2.5 times control. The solution HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% is typically used for continuous infusion; dose should be adjusted based on patient weight and aPTT.
None Documented
None Documented
Terminal elimination half-life is 11–12 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 1.5-2 hours (mean 1.6 h) at therapeutic doses, but is dose-dependent: 30-60 min after 25 U/kg, 1-2 h after 100-200 U/kg, and 2.5-5 h after 400-800 U/kg. Half-life is prolonged in hepatic or renal impairment.
Renal excretion of unchanged drug accounts for approximately 30% of the dose; biliary/fecal elimination accounts for about 70% (60% fecal as parent drug and metabolites, 10% biliary).
Heparin is eliminated primarily via the reticuloendothelial system and renal excretion. Approximately 50% is excreted unchanged in urine via saturable zero-order kinetics, with the remainder metabolized to uroheparin and other inactive metabolites. Biliary/fecal excretion is negligible (<5%).
Category C
Category A/B
Anticoagulant
Anticoagulant